STON1

Across TCGA pan-cancer cohorts, STON1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of STON1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where STON1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types STON1 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where STON1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STON1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	−0.533	<.001	10	view →
LUAD	Male	III,IV	−0.732	<.001	9	view →
LSCC	Male	II,III,IV	−0.359	<.001	6	view →
PDAC	Female	All	+0.767	.001	4	view →
HNSC	All	All	+0.347	.027	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

STON1–CCRCC

Open the CCRCC breakdown →